Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis

被引：0
|
作者：
Timothy J. Brown
Ronac Mamtani
Phyllis A. Gimotty
Thomas B. Karasic
Yu-Xiao Yang
机构：
[1] University of Pennsylvania,Abramson Cancer Center
[2] University of Pennsylvania,Penn Center for Cancer Care Innovation
[3] University of Pennsylvania,Department of Biostatistics, Epidemiology, and Informatics
[4] University of Pennsylvania,Department of Medicine, Division of Gastroenterology
[5] Corporal Michael J Crescenz Veterans Affairs Medical Center,Medicine Services, GI Section
来源：
Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷
关键词：
Hepatocellular carcinoma; NASH; Immunotherapy; Outcomes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2345 / 2354
页数：9
相关论文
共 50 条
  • [1] Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis
    Brown, Timothy J.
    Mamtani, Ronac
    Gimotty, Phyllis A.
    Karasic, Thomas B.
    Yang, Yu-Xiao
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (06) : 2345 - 2354
  • [2] Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies
    Wang, Bi-Cheng
    Kuang, Bo-Hua
    Lin, Guo-He
    TARGETED ONCOLOGY, 2024, 19 (02) : 203 - 212
  • [3] Real-world experience of atezolizumab/bevacizumab in hepatocellular carcinoma
    Ha, Yeonjung
    Cheon, Jaekyung
    Hwang, Seong Gyu
    Chon, Hong Jae
    JOURNAL OF HEPATOLOGY, 2021, 75 : S526 - S527
  • [4] Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies
    Bi-Cheng Wang
    Bo-Hua Kuang
    Guo-He Lin
    Targeted Oncology, 2024, 19 : 203 - 212
  • [5] Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study
    Kim, Beom Kyung
    Cheon, Jaekyung
    Kim, Hyeyeong
    Kang, Beodeul
    Ha, Yeonjung
    Kim, Do Young
    Hwang, Seong Gyu
    Chon, Young Eun
    Chon, Hong Jae
    CANCERS, 2022, 14 (07)
  • [6] The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey
    Akyildiz, Arif
    Guven, Deniz Can
    Ozluk, Ahmet Anil
    Ismayilov, Rashad
    Mutlu, Emel
    Unal, Olcun Umit
    Yildiz, Ibrahim
    Iriagac, Yakup
    Turhal, Serdar
    Akbas, Sinem
    Bayram, Ertugrul
    Telli, Tugba Akin
    Turkoz, Fatma Paksoy
    Ozcelik, Melike
    Erciyestepe, Mert
    Selvi, Oguzhan
    Gulbagci, Burcu
    Erturk, Ismail
    Isleyen, Zehra Sucuoglu
    Kahraman, Seda
    Akdag, Mutianur Ozkorkmaz
    Hamitoglu, Buket
    Unek, Ilkay Tugba
    Unal, Caglar
    Hacibekiroglu, Ilhan
    Arslan, Cagatay
    Azizy, Abdulmunir
    Helvaci, Kaan
    Demirci, Umut
    Dizdar, Omer
    Basaran, Mert
    Goker, Erdem
    Sendur, Mehmet Ali
    Yalcin, Suayib
    MEDICINE, 2023, 102 (45) : E35950
  • [7] Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
    Rossari, F.
    Tada, T.
    Shimose, S.
    Kudo, M.
    Yoo, C.
    Cheon, J.
    Finkelmeier, F.
    Lim, H. Y.
    Presa, J.
    Masi, G.
    Bergamo, F.
    Amadeo, E.
    Vitiello, F.
    Foti, S.
    Persano, M.
    Piscaglia, F.
    Scartozzi, M.
    Cascinu, S.
    Rimini, M.
    Gardini, A. Casadei
    ANNALS OF ONCOLOGY, 2023, 34 : S1547 - S1547
  • [8] Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study
    Rossari, Federico
    Tada, Toshifumi
    Suda, Goki
    Shimose, Shigeo
    Kudo, Masatoshi
    Yoo, Changhoon
    Cheon, Jaekyung
    Finkelmeier, Fabian
    Lim, Ho Yeong
    Presa, Jose
    Masi, Gianluca
    Bergamo, Francesca
    Amadeo, Elisabeth
    Vitiello, Francesco
    Kumada, Takashi
    Sakamoto, Naoya
    Iwamoto, Hideki
    Aoki, Tomoko
    Chon, Hong Jae
    Himmelsbach, Vera
    Iavarone, Massimo
    Cabibbo, Giuseppe
    Montes, Margarida
    Foschi, Francesco Giuseppe
    Vivaldi, Caterina
    Solda, Caterina
    Sho, Takuya
    Niizeki, Takashi
    Nishida, Naoshi
    Steup, Christoph
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Shimada, Noritomo
    Kawata, Kazuhito
    Hiraoka, Atsushi
    LIVER CANCER, 2024, 13 (05) : 522 - 536
  • [9] COMPARISON EFFICACY AND SAFETY BETWEEN ATEZOLIZUMAB PLUS BEVACIZUMAB AND LENVATINIB AS FIRST-LINE SYSTEMIC THERAPY FOR HEPATOCELLULAR CARCINOMA: A REAL-WORLD STUDY
    Boonkaya, Sangdao
    Thanapirom, Kessarin
    Siripon, Nipaporn
    Thaimai, Panarat
    Ananchuensook, Prooksa
    Sriphoosanaphan, Supachaya
    Tanasanvimon, Surbpong
    Treeprasertsuk, Sombat
    Komolmit, Piyawat
    GASTROENTEROLOGY, 2024, 166 (05) : S73 - S74
  • [10] Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries
    Lee, Choong-kun
    Yoo, Changhoon
    Hong, Jung Yong
    Park, Se Jun
    Kim, Jin Won
    Tai, David Wai Meng
    Kim, Hyeyeong
    Korphaisarn, Krittiya
    Tanasanvimon, Suebpong
    Chen, San-Chi
    Kim, Ju Won
    Kim, Ilhwan
    Kim, Moonho
    Choo, Joan
    Oh, Sang-Bo
    Chen, Ching-Tso
    Bae, Woo Kyun
    Kim, Hongsik
    Huh, Seok Jae
    Yen, Chia-Jui
    Park, Sejung
    Lee, Dong Ki
    Chan, Landon Long
    Kang, Beodeul
    Kang, Minsu
    Sundar, Raghav
    Choi, Hye Jin
    Chan, Stephen Lam
    Chon, Hong Jae
    Lee, Myung-Ah
    LIVER CANCER, 2024,
12345